L. Campos

发表

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.

J. Nemunaitis, R. Hermann, J. Bendell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors

David C. Smith, S. Ramalingam, H. Safran, 2016, The oncologist.

Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer.

J. Hainsworth, L. Campos, R. Birch, 2003, The oncologist.

Direct Visualization of F-18-Fluorodeoxyglucose Accumulation in Feces

L. Campos, D. Wan, M. Miró-Quesada, 2009 .

Chemokine expression in tumor-to-tumor metastasis.

L. Camacho, L. Campos, B. Kemp, 2010, Oncology letters.

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin‐containing regimens

G. Hortobagyi, A. Buzdar, C. Wiseman, 1981, Cancer.

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment

J. Hajdenberg, R. Figlin, R. Bukowski, 2007 .

Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.

Suzanne F. Jones, J. Bendell, L. Camacho, 2010 .

Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma

R. Figlin, I. Henderson, J. Stephenson, 2008 .

Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)

I. Henderson, J. Stephenson, L. Campos, 2007 .

Autoimmune hemolytic anemia presenting concurrently with thrombotic thrombocytopenic purpura

L. Campos, J. Peguero, Munaf Al-Kadhimi, 2016, Case Reports International.

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.

J. Ajani, R. Winn, R. Pazdur, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma

D. Mahalingam, L. Campos, J. Rowe, 2019, Cancers.

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices

V. Morrison, D. Hershman, B. Ding, 2007, Journal of managed care pharmacy : JMCP.

Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer

M. Birrer, L. Camacho, M. Mita, 2016, Targeted Oncology.

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer

L. Camacho, B. Bienvenu, J. Waymack, 2017, Journal of Cancer.

Syringoid eccrine carcinoma: A case report and literature review of therapeutic options

L. Campos, J. Peguero, Munaf Al-Kadhimi, 2016 .

High‐Dose Chemotherapy with Peripheral Blood Stem Cell Support for Operable Locally Advanced Noninflammatory Carcinoma of the Breast

M. Murphy, L. Campos, L. Schwartzberg, 1999, The breast journal.

Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report.

G. Hortobagyi, E. Gehan, A. Buzdar, 1979, JAMA.

Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

J. Nemunaitis, R. Hermann, J. Bendell, 2010 .

Pegfilgrastim and filgrastim patterns of use in community oncology practices: Results of the ACCEPT study

L. Campos, L. Meza, V. Charu, 2005 .

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

D. Gandara, D. Planchard, S. Ramalingam, 2014 .

Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: outpatient administration in community cancer centers.

J. Hainsworth, F. Greco, L. Campos, 1998, American journal of clinical oncology.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.

L. Campos, C. Bedell, D. Richards, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.